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Abstract
Background: Smoking is the number one cause of preventable morbidity and mortality globally and although
many countries have invested heavily in smoking cessation programs, 21% of the global population still smoke.
Post cessation weight gain has been identified as a barrier to attempting cessation and is implicated in the high
rates of relapse. Naltrexone has been touted as a possible solution to address post smoking cessation weight gain.
Results: The results from seven original studies assessing the effectiveness of naltrexone in combination with
existing smoking cessation medications to attenuate post smoking cessation weight gain were obtained and
critically reviewed. Five returned positive results and two returned results that were statistically insignificant. The
positive results were seen more often in those identified as more likely to exhibit hedonic eating behaviour for
example women and participants who were categorised as overweight or obese.
Conclusion: The evidence suggests further investigation in to a combination of naltrexone and approved smoking
cessation medications is warranted and could provide a solution to attenuate post smoking cessation weight gain
especially in women and those classified as overweight or obese. This may provide the tool required to remove a
perceived barrier to smoking cessation and improve global statistics.
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Background
Tobacco smoking is the leading cause of preventable
morbidity and mortality globally and is causally linked to
over five million deaths per year [1, 2]. There is over-
whelming evidence that indicates it is the primary cause
of nine different cancers and it is also implicated as a
risk factor for stroke, cardiovascular disease, and numerous
respiratory disorders [3]. Smoking affects every organ in
the body and the financial burden for already stretched
healthcare systems is crippling. With guidance from the
World Health Organisation’s framework convention for
tobacco control, many countries have invested in smoking
cessation programs to try and reduce the scourge [4, 5].
New Zealand is regarded as a leader in tobacco control
with bold initiatives including Smokefree 2025 (less
than 5 % of the population smoking by 2025) paving
the way [6]. However, although smoking rates have
been steadily reducing there are still sectors within society
that are overrepresented in the statistics. For example, ac-
cording to the Ministry of Health, New Zealand Health
Survey 2014/2015, 42 % of Maori women reported being
current regular smokers, in comparison with 17 % of the
total population [7]. Under article three of the Treaty of
Waitangi, New Zealand’s founding document, the Crown
has an obligation to ensure Maori are afforded oritetanga
(equity) with non-Maori so action is needed [8]. Initiatives
to improve smoking cessation statistics have been
employed in New Zealand and globally. Education relating
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to the health consequences of smoking tobacco is wide-
spread and is accompanied by governmental policies to re-
strict the purchase and use, yet there are still too many
individuals not embracing the opportunity to improve
their health [9, 10]. A number of studies have been
conducted to identify any perceived barriers deterring
individuals from attempting cessation and furthermore in-
vestigating why some relapse. Several of these studies con-
cluded a fear of weight gain was a common barrier for
cessation and contributed to relapse [6, 11–14]. This in-
formation was the driver behind researchers initiating in-
vestigations into the effectiveness of pharmacological aids
to attenuate weight gain post smoking cessation. The aim
of this review is to assess the effectiveness of naltrexone
combined with currently available smoking cessation
medications to reduce post smoking cessation weight gain.
The current literature will be reviewed with the objective
being to investigate a possible solution that may remove a
perceived barrier to smoking cessation and achieve the
overall goal of a reduction in the number of smokers thus
reducing the impact on individuals and health systems. A
brief outline of the literature highlighting perceived barriers
to smoking cessation and causes of relapse will be followed
by an outline of the pharmacological aspects of naltrexone
that support an investigation in to its use for weight control
post smoking cessation. A summary of the current research
obtained will be followed by a critical discussion on the
findings and the conclusion will summarise these findings
and identify any gaps in the research.
Despite global efforts to encourage smoking cessation
and evidence of an overall decline in the number of
smokers, 21 % of individuals aged over fifteen still smoke
[1, 15]. Studies have revealed more than two thirds of
current smokers wish to quit; however only half will
attempt cessation and approximately two thirds of ab-
stainers’ relapse in the first year [12, 16, 17]. This high-
lights a need for advancements in cessation methods to
reach those for whom the current initiatives are not
working [6, 12, 13]. Although research has revealed evi-
dence that the majority of smokers are aware of the
harm smoking causes [18], it also highlights a fear of
weight gain as being a prevalent deterrent for attempting
cessation, and a contributing factor to relapse with both
these factors underpinned by the belief that smoking to-
bacco helps control weight [13, 19, 20].
With the introduction of tobacco, tobacco companies
marketed cigarettes as a weight control product target-
ing women and this ideological belief appears to still be
present in a number of smokers today [14, 21–23]. It is
also apparent from the literature women allude to the
fear of weight gain as being a barrier to smoking cessa-
tion more often than men and are three to four times
more likely to relapse due to weight gain; however, it is
acknowledged that some men do admit to believing
smoking helps regulate their weight [12, 14, 22, 23].
Medical literature gives some substance to this notion of
tobacco smoking physiologically regulating weight and
impacting on eating behaviour. There is experimental
evidence to suggest nicotine from tobacco smoking is as-
sociated with neuroadaptations that suppress reward
driven eating and impact on resting metabolic rates whilst
also increasing energy expenditure [13, 14, 19, 21, 23].
During smoking cessation and the subsequent withdrawal
of nicotine, these anorectic effects are supressed and with-
out action to control previously blunted eating behaviours
weight gain is likely [14, 21, 24]. Studies have shown up to
80 % of smokers gain on average between two and five ki-
lograms in the first year after cessation; however, some
will gain in excess of ten kilograms and women are more
likely than men to gain substantial weight [1, 21–23, 25].
It was also recognised the average number of cigarettes
smoked daily had a direct correlation to the amount of
post cessation weight gain, the more an individual
smoked the more weight they tended to gain post ces-
sation [1, 14, 21, 22, 24, 25]. In a prospective study per-
formed in New Zealand it was noted that even though
smokers who quit gained more weight than those who
continued to smoke, in general the gain was no more
than those of similar age, who had never smoked, gained
over the same time [26]. Despite varying evidence that
suggests cigarette smoking can be implicated in weight
control, other evidence reveals a substantial number of
current smokers are classed as obese [11, 14, 24, 27]. One
must question which came first the obesity or the smoking
and are these smokers trying to reduce the chance of
further weight gain by smoking? Yu et al., (2014) [24]
found that obese smokers were less likely to be prescribed
smoking cessation medication and questioned whether
this was due to the fear of further weight gain preventing
them seeking help or whether health professionals fear of
further weight gain stopped them prescribing. Further-
more, studies have shown any weight gain post smoking
cessation can be attributed to an increase in the incidence
of type two diabetes and contributes to an increase in the
risk of hypertension by up to 30 % which surmounts to
very high risk for those already obese [11, 13, 21, 22, 25].
In summary the literature supports the theory that post
cessation weight gain is a warranted barrier to attempting
cessation and increasing the risk of relapse especially in
women. Therefore, offering a solution to decrease the risk
of weight gain post cessation may encourage and help in-
dividuals still smoking to successfully and permanently
quit. First it is important to ascertain if the currently avail-
able cessation medications have an effect on post cessa-
tion weight gain.
To date clinical trials testing various currently avail-
able smoking cessation medications capacity to attenuate
post cessation weight gain alone have returned mixed
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results. The most commonly used cessation medications
include nicotine replacement therapy in the form of
patches, bupropion, and varenicline [10]. Yang et al.,
(2016) [28], found that although participants receiving
bupropion appeared to gain less weight than participants
using varenicline, once the results were adjusted for con-
founding factors they were deemed to be statistically in-
significant. Alternately Schnoll et al., (2012) [20] found
participants using nicotine patches for longer than the
standard cessation period appeared to gain less weight
than those using them for the standard time frame and
adherence to patch use was greater in the longer term
participants. However, a limitation of this study was that
patch adherence was determined by self-reporting which
may affect the validity of the results [29]. Bush et al.,
(2012) [22], trialled cognitive behavioural therapy as a
combination with nicotine patches to attenuate post ces-
sation weight gain with positive results; however, once
again self-reporting and surveys were used to acquire re-
sults. The mixed results received from these studies war-
rant further investigation in to alternate therapies such
as combination pharmacotherapies. Naltrexone com-
bined with existing cessation medications has been tou-
ted as a possible pharmacological combination that may
be successful in helping to achieve this [9, 17, 30–34].
Naltrexone
Naltrexone is a semi synthetic opioid that acts as an
antagonist at the μ receptors in the endogenous opioid
system in the brain and is currently approved to treat
opioid addiction and alcohol dependence [35, 36]. It has
also recently been approved as an adjunct treatment to
assist weight loss in morbidly obese individuals in the
United States [34–37]. The endogenous opioid system
has been implicated in hedonic eating behaviours and
evidence suggests there is interaction between the opioid
and nicotinic system, which is implicated in smoking ad-
diction [17, 19, 31, 34, 38]. As mentioned previously post
cessation weight gain can be partly attributed to hedonic
eating behaviours that were formerly blunted by nicotine
from tobacco smoking. Other sources of nicotine have
also been proven to decrease hedonic eating in non-
smokers which further supports the theory that with-
drawing nicotine can increase the likelihood of hedonic
eating behaviour leading to weight gain [19,]. Naltrexone
has been proven to reduce eating behaviour synonymous
with the endogenous opioid pathway by stopping the re-
warding effects and increasing aversion to palatable
foods (those high in fat and sugar) [19, 35–38]. Murray
et al., (2014) [38], conducted a study to test the efficacy
of naltrexone to blunt the desire for palatable food, and
found participants administered naltrexone displayed a
decreased response in reward stimuli to palatable foods
and an increased aversion to other foods when compared
with placebo. A systematic review and meta -analysis in-
vestigating the use of opioid antagonists including naltrex-
one as a monotherapy for smoking cessation completed
by David et al., (2014) [39], concluded that there was no
evidence of any benefit of naltrexone on its own as a
therapy to aid smoking cessation. However, there is evi-
dence that supports naltrexone being an effective tool to
halt eating behaviour driven by effects of the opioid
pathway which are perceived to be enhanced by smoking
cessation. The possibility that it could be effective as a
pharmacological combination with approved smoking ces-
sation medications to reduce post smoking cessation
weight gain warranted further investigation and a number
of studies have been conducted.
Method
To procure the current relevant literature for review a
thorough search of the Auckland University of Technology
library including the databases, CINAHL, EBSCO Health,
Google Scholar, Medline, ProQuest, Science Direct and
Scopus was performed. Each source was individually
searched using the keywords and phrases “naltrexone”,
“smoking cessation”, “weight reduction”, “opioid
antagonists”, “barriers to smoking cessation”, “obesity
and smoking cessation”, and “tobacco control strate-
gies”. To access studies directly relating to the use of
naltrexone for post smoking cessation weight reduction
a combination of these phrases was used: “naltrexone”
and “smoking cessation” and “weight reduction”. Fur-
thermore, to ensure the results returned were current
and from credible sources further parameters were set.
Primarily studies that were published in peer reviewed
journals and had been conducted within the past ten
years were included. With advancements in pharmaco-
therapy to aid smoking cessation the authors deemed it
necessary to consider research applicable to currently
available smoking cessation medications hence any
studies pre-dating 2006 were excluded as were studies
using monotherapy: however, these studies were utilised
for background information.
Discussion
Effectiveness of naltrexone to attenuate post smoking
cessation
Several studies have tested the effectiveness of naltrex-
one to attenuate post smoking cessation weight gain. Of
the seven studies found, five were double blinded rando-
mised placebo controlled trials (RCT), one was an open
label study with a control group, and one was an open
label study with no control group. The studies all mea-
sured outcomes within the fifty-two weeks immediately
post cessation which is in line with evidence suggesting
the greatest weight gain usually occurs in the first year
post cessation [21]. Five out of seven studies returned
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positive results suggesting a naltrexone combination
could be effective in reducing post smoking cessation
weight gain while two found results that were statisti-
cally insignificant [9, 10, 17, 32, 33, 40, 41]. Four of the
studies returning positive results used a combination
of nicotine patches and naltrexone and the remaining
one used bupropion combined with the naltrexone
[10, 32, 33, 41]. One of the studies that revealed statis-
tically insignificant results used the nicotine patch
combination and the other the bupropion [9, 17]. Of
note, there appears to be no current studies trialling a
combination including the other most commonly pre-
scribed smoking cessation medication, varenicline. In pre-
vious studies, the two medications that were trialled,
nicotine patches and bupropion, although results were
deemed statistically insignificant appeared to have more
positive effect on reducing post cessation weight gain as a
monotherapy than varenicline [28]. However, varenicline
has returned the best long term abstinence rates and is
generally considered the most effective smoking cessation
medication [10, 28]. One must question why a combin-
ation of naltrexone and varenicline appears to have not
been tested thus far when existing evidence suggests it
may produce better abstinence rates. Furthermore, having
reviewed the pharmacological datasheet on varenicline
there does not appear to be any identified interactions be-
tween naltrexone and varenicline that could prevent a
combination being prescribed [42]. Nevertheless, nicotine
patches with naltrexone were the most common combin-
ation used in the studies, this could possibly be due to less
reported side effects from nicotine patch use as a mono-
therapy compared with bupropion and varenicline [43]. It
is important to acknowledge all of the studies included
pertaining to the effectiveness of naltrexone combined
with smoking cessation medication to attenuate post ces-
sation weight gain were conducted in the United States of
America and several researchers were involved in more
than one of the studies. Upon analysis overall the available
studies returned varying results. A number of common
themes including the role of hedonic eating in post cessa-
tion weight gain and treatment implications, abstinence
rates, and the tolerability of naltrexone, were apparent.
Sex specific effectiveness of naltrexone
King et al., (2012) [32] and King et al., (2013a) [33] initi-
ated studies where the aim was to assess the effective-
ness and ascertain if there were any sex specific results
when using a combination of naltrexone, nicotine
patches, and cognitive behavioural treatment (CBT) to
attenuate post cessation weight gain. Both the studies
found that the women in the studies showed signifi-
cantly reduced weight gain compared with the placebo
group whereas the men did not. However, the women in
the placebo group had greater weight gain than the men
in the placebo group. A possible explanation for these
results as mentioned previously could be due to the fact
that some women have been shown to have lower cogni-
tive control of brain responses to food stimuli and are
somewhat predisposed to hedonic eating behaviour
which during smoking is blunted by the effects of nico-
tine. Once nicotine is withdrawn and hedonic behaviours
are amplified weight gain is inevitable if control is not
regained hence those taking naltrexone gained less
weight [31]. On the other hand, the results of a study
undertaken by Toll et al., (2010) [9], investigating the ef-
fects of naltrexone combined with nicotine patches and
CBT in highly weight concerned smokers returned nega-
tive results and may further support the notion that the
lack of cognitive control apparent in some women may
be implicated in post cessation weight gain. Participants
included in this study were recruited according to their
score on a weight concern scale and as women scored
the highest the study included more women than men.
The results showed that there was no significant difference
in weight gain between the treatment group (receiving
naltrexone) and the placebo group. A suggested reason for
this was participants already had cognitive control over
their eating and although advised not to, may have dieted
throughout treatment [9]. Dieting is regarded as counter-
productive during smoking cessation as it is suggested
those who restrain their eating habits because of fear of
weight gain are more likely to relapse due to a sub
conscious reinforcement of smoking as a weight control
mechanism [9]. This may offer an explanation for the
extraordinarily high dropout rate from this particular study
[9, 19]. The evidence from these studies suggest that to
some extent naltrexone may be more effective for women
than men due to commonly perceived differences in
physiological driven eating behaviours [9].
Use of naltrexone in obese patients
Wilcox et al., (2010) [10], tested the use of a naltrexone
with bupropion combination and behavioural therapies
in already overweight and obese smokers. On comple-
tion of the study it was found there was no significant
change in the weight measurements of participants when
compared with their baseline measures. Existing evi-
dence supports the perception that overweight and
obese individuals may have low conscious control over
their eating habits and are also prone to display hedonic
eating behaviour [11, 19, 34, 35]. The study results sup-
port the hypothesis that naltrexone may curb this behav-
iour leading to reduced weight gain post smoking
cessation [10]. However, there was no control group in
this study so there is no evidence to prove the effects
were not produced by the bupropion or behavioural
therapy. In fact, efficacy studies indicate that specialised
behavioural therapy has been successful in suppressing
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weight gain over the short term during smoking cessa-
tion [22]. Whilst King et al., (2012) [32] also included in-
dividuals in their research that were classed as
overweight and obese the results were not stratified by
body mass index. It is hard to determine if the positive
results were due to the inclusion of obese and over-
weight participants. However, if compared with the Toll
et al., (2010) [9], study which only included highly
weight concerned smokers who fitted in the normal
weight category and returned negative results, assump-
tions may be made that suggest the results could have
been positive due to the inclusion of overweight and obese
participants who were more likely to exhibit hedonic eat-
ing behaviour. There is some suggestion that naltrexone
may be effective in overweight or obese individuals to at-
tenuate post cessation weight gain. Even though the aim
of this review is to assess the effectiveness of naltrexone
regarding weight gain it is also important to consider the
effect of naltrexone on abstinence rates. It would be coun-
terproductive to offer a weight reduction pharmacother-
apy that negatively affects abstinence rates.
Effect of naltrexone on cessation rates
There are mixed results reported in the literature re-
garding the possible effect of naltrexone on cessation
rates. In two studies that extrapolated sex specific re-
sults, the men from the treatment group returned better
abstinence rates than the placebo group, and the women
in the treatment group [32, 33]. In contrast Toll et al.,
(2010) [9], found in a similar RCT combining nicotine
patches and CBT with naltrexone that abstinence rates
were greater in the placebo group than the treatment
group. However, when considering the results from the
sex stratified studies the ratio of men to women in the
Toll et al., 2010 [9] study placebo group may have im-
pacted on the results and furthermore according to
Walker et al., (2016) [15], evidence shows that men are
more likely than women to achieve and maintain abstin-
ence. Whilst King et al., (2013b) [17], Wilcox et al.,
(2010) [10] and Toll et al., (2010) [9] found naltrexone
appeared to reduce the urge to smoke and the number
of cigarettes smoked pre cessation, this could have been
attributed to the cessation medications, nicotine patches
and bupropion, as during an investigation by Rohsenow
et al., (2007) [44] in to the effects of naltrexone on
smoking cessation it was found naltrexone did not re-
duce the urge to smoke after ten hours of nicotine
deprivation. In a small open label study conducted by
Toll et al., (2008) [41] with the aim of testing what effect
a combination of bupropion and naltrexone may have
on weight gain post cessation, the participants receiving
bupropion monotherapy maintained a better rate of ab-
stinence post treatment than those taking the naltrexone
combination. However, due the extremely small number
of participants in this study the results cannot be
deemed as indicative of expected results in a larger
population [29]. Whilst all previously mentioned studies
trialled combinations that included either 25 mg or
50 mg doses of naltrexone O’Malley et al., (2006) [40],
tested the effects of a combination including a 100 mg
dose of naltrexone, nicotine patch and CBT and found
that those receiving the highest dose of naltrexone,
100 mg, returned better abstinence rates during the
treatment period than those in the lower dose groups
and those receiving placebo but these results were not
observed in a post treatment follow up. It appears that
whilst naltrexone may have shown better results in ab-
stinence in men in two of the studies overall the placebo
groups appeared to sustain a higher rate of abstinence.
An important factor that these studies appeared to neg-
lect was the number of previous quit attempts partici-
pants had made. Although several excluded those
individuals who had made recent quit attempts, evidence
from large study by Chaiton et al., (2016) [45] highlights
it may take a smoker on average thirty attempts to quit
before being successful. This raises questions on the
validity of results correlating abstinence to type of ther-
apy used unless quit attempts have been included as a
possible confounder [29]. Tolerability and adherence to
therapies can also effect overall results but were well
documented during the included studies analyses.
Side effects of naltrexone use in smoking cessation
therapy
The most common side effects attributed to naltrexone
throughout the studies were nausea and dizziness; how-
ever, these were generally reported to be mild and on
the whole were said not to have had an effect on overall
adherence rates [9, 10, 17, 32, 33, 41]. It is important to
note that nausea and dizziness are also common side ef-
fects of nicotine patches and even though there ap-
peared to be less incidence in the placebo groups there
is no definitive evidence to surmise which pharmaco-
therapy caused these effects as every individual reacts
differently and more in the treatment group may have
reacted to the nicotine patch [20, 46]. There was one ex-
ception to the generally acceptable adherence rates,
O’Malley et al., (2006) [40] found that participants re-
ceiving a naltrexone dose of 100 mg did not show as
greater compliance rates as those receiving the lower
doses of 25 mg or 50 mg due to the persistence of un-
pleasant side effects. At the 100 mg dose there were also
four cases of increased liver function values deemed to
be outside the safe threshold and once naltrexone was
stopped they returned to normal [40]. Liver function
tests from the lower dose participants in the O’Malley et
al., (2006) [40] study and the Toll et al., (2010) [9] study
were all normal and within the safe range throughout
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the duration of treatment. Furthermore, in the O’Malley
et al., (2006) [40] study participants in the 25 mg treat-
ment group reported side effects that were no different
to those experienced by participants in the placebo
group. Overall evidence suggests that 25 mg and 50 mg
naltrexone were well received with few side effects and
generally good tolerability.
Conclusions
In conclusion the evidence suggests that naltrexone com-
bined with existing approved smoking cessation medica-
tions may be an effective pharmacotherapy to attenuate
post smoking cessation weight gain in individuals whom
are more likely to display hedonic eating behaviours, for ex-
ample some women and those individuals who are already
overweight or obese. This is promising as the literature reit-
erates that women and obese individuals are more likely to
not attempt cessation due to fear of weight gain and fur-
thermore women are three to four times more likely than
men to relapse because of weight gain. A noticeable gap in
the research pertained to the apparent exclusion in trials of
a naltrexone combination with varenicline which is deemed
to be the cessation medication that produces the best long
term abstinence rates. Further research trialling varenicline
and stratifying results by gender and weight status is
recommended to find the most effective combination.
Whilst abstinence rates did not appear to be significantly
affected by the use of naltrexone and although men ap-
peared to maintain more favourable abstinence results
whilst receiving treatment with a naltrexone combination,
without further gender specific research there is not enough
evidence to draw conclusions other than naltrexone does
not appear to have any negative effects on abstinence rates.
Overall the combinations including the 25 mg and 50 mg
naltrexone components were well tolerated by study partic-
ipants and adherence rates were satisfactory. With smoking
still causing the greatest number of preventable deaths glo-
bally and weight gain being touted as a significant barrier to
attempting cessation whilst also contributing to relapse, the
evidence suggests the use of naltrexone to attenuate post
cessation weight gain may provide a solution. In a New
Zealand context although regarded as leaders in tobacco
control there are still sectors of society that are grossly
overrepresented in smoking statistics and need to be
reached. Māori women are one such group and with the
positive results seen in the trials for women a naltrexone
combination may help reduce these numbers by removing
an identified barrier to cessation. With further research to
find the optimal combination naltrexone could provide the
solution to removing this barrier thus helping increase glo-
bal smoking cessation rates and relieving unnecessary bur-
den on individuals and healthcare systems. It may
provide the impetus New Zealand needs to reach the
goal of Smokefree 2025.
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